Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$1.82 USD
-0.02 (-1.09%)
Updated Apr 22, 2024 11:40 AM ET
After-Market: $1.92 +0.10 (5.49%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Cognition Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 30 | 42 | 55 | 5 | -99,999 |
Receivables | 1 | 4 | 2 | 1 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 3 | 2 | 2 | 1 | NA |
Total Current Assets | 34 | 48 | 59 | 7 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 2 | 0 | 0 | NA |
Total Assets | 35 | 50 | 59 | 7 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 4 | 3 | 4 | 2 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 4 | 2 | 2 | 1 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 2 | 2 | 2 | 0 | NA |
Total Current Liabilities | 10 | 8 | 8 | 3 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 12 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 2 | 0 | 4 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 11 | 10 | 8 | 20 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 55 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 166 | 156 | 145 | 0 | NA |
Retained Earnings | -141 | -115 | -94 | -68 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 24 | 40 | 51 | -13 | NA |
Total Liabilities & Shareholder's Equity | 35 | 50 | 59 | 7 | NA |
Total Common Equity | 24 | 40 | 51 | -68 | 0 |
Shares Outstanding | 32.10 | 28.90 | 22.00 | NA | NA |
Book Value Per Share | 0.76 | 1.39 | 2.33 | 0.00 | 0.00 |
Fiscal Year End for Cognition Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 30 | 33 | 37 | 39 |
Receivables | NA | 1 | 2 | 2 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 1 | 2 | 2 |
Total Current Assets | NA | 34 | 36 | 42 | 43 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 2 | 1 | 2 |
Total Assets | NA | 35 | 39 | 44 | 46 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 3 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 4 | 2 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 1 | 1 | 2 |
Total Current Liabilities | NA | 10 | 8 | 8 | 7 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 11 | 10 | 10 | 10 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 166 | 162 | 161 | 158 |
Retained Earnings | NA | -141 | -133 | -126 | -122 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 24 | 29 | 34 | 36 |
Total Liabilities & Shareholder's Equity | NA | 35 | 39 | 44 | 46 |
Total Common Equity | 0 | 24 | 29 | 34 | 36 |
Shares Outstanding | 39.00 | 32.10 | 30.30 | 29.20 | 29.20 |
Book Value Per Share | 0.00 | 0.76 | 0.95 | 1.18 | 1.23 |